
Cristina SuÃ;rez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2635069/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <i>TP53</i> Solid Tumors and Acute Leukemia. Clinical Cancer Research, 2022, 28, 870-881.	3.2	32
2	Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 292-303.	5.1	42
3	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncology, 2022, 8, 275.	3.4	75
4	Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. European Urology, 2022, 82, 212-222.	0.9	56
5	Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open, 2022, 5, e2216379.	2.8	10
6	Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 888-898.	5.1	114
7	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. European Urology, 2021, 79, 200-211.	0.9	76
8	Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis. European Radiology, 2021, 31, 1460-1470.	2.3	87
9	The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC) Journal of Clinical Oncology, 2021, 39, 339-339.	0.8	6
10	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2021, 384, 829-841.	13.9	961
11	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2021, 39, 1029-1039.	0.8	145
12	Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies. Current Opinion in Urology, 2021, 31, 242-248.	0.9	4
13	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology, 2021, 299, 109-119.	3.6	54
14	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. European Urology, 2021, 79, 665-673.	0.9	20
15	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. European Urology Oncology, 2021, 4, 456-463.	2.6	18
16	PARP inhibitors in advanced prostate cancer: when to use them?. Endocrine-Related Cancer, 2021, 28, T79-T93.	1.6	5
17	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. Journal of Clinical Oncology, 2021, 39, 3725-3736.	0.8	69
18	ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Annals of Oncology, 2021, 32, 1511-1519.	0.6	113

CRISTINA SUÃiREZ

#	Article	IF	CITATIONS
19	A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. Oncology Research and Treatment, 2021, 44, 547-556.	0.8	11
20	Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. European Urology, 2021, , .	0.9	9
21	Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2020, 10, 594023.	1.3	7
22	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2020, 21, 1574-1588.	5.1	324
23	The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor. Cancer Treatment Reviews, 2020, 86, 102000.	3.4	19
24	Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. Investigational New Drugs, 2020, 38, 1570-1579.	1.2	70
25	SEOM clinical guideline for treatment of kidney cancer (2019). Clinical and Translational Oncology, 2020, 22, 256-269.	1.2	18
26	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-NaÃ⁻ve Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 2506-2514.	3.2	20
27	Patientâ€reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. BJU International, 2020, 126, 73-82.	1.3	19
28	Kidney cancer PDOXs reveal patientâ€specific proâ€malignant effects of antiangiogenics and its molecular traits. EMBO Molecular Medicine, 2020, 12, e11889.	3.3	4
29	Latest progress in molecular biology and treatment in genitourinary tumours. Clinical and Translational Oncology, 2020, 22, 2175-2195.	1.2	2
30	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nature Medicine, 2019, 25, 1706-1714.	15.2	407
31	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415.	6.3	778
32	Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study. Medical Oncology, 2019, 36, 29.	1.2	0
33	Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2019, 103, 344-352.	0.4	5
34	KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC) Journal of Clinical Oncology, 2019, 37, 4569-4569.	0.8	23
35	A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO) Journal of Clinical Oncology, 2019, 37, 545-545.	0.8	40
36	Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC) Journal of Clinical Oncology, 2019, 37, 550-550.	0.8	3

CRISTINA SUÃIREZ

#	Article	IF	CITATIONS
37	Nanoparticles as theranostic vehicles in prostate cancer. Annals of Translational Medicine, 2019, 7, S29-S29.	0.7	1
38	Prognostic and Predictive Factors for Renal Cell Carcinoma. Targeted Oncology, 2018, 13, 309-331.	1.7	5
39	SEOM clinical guideline for treatment of kidney cancer (2017). Clinical and Translational Oncology, 2018, 20, 47-56.	1.2	15
40	Detection of circulating tumor DNA for advanced bladder cancer: where are we going?. Translational Andrology and Urology, 2018, 7, S101-S103.	0.6	1
41	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British Journal of Cancer, 2018, 119, 663-669.	2.9	66
42	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Medicine, 2018, 24, 749-757.	15.2	900
43	A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS) Journal of Clinical Oncology, 2018, 36, 4506-4506.	0.8	69
44	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2018, 36, 4511-4511.	0.8	12
45	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). Journal of Clinical Oncology, 2018, 36, 578-578.	0.8	164
46	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	3.4	80
47	Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib. Scientific Reports, 2017, 7, 41371.	1.6	3
48	Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. Targeted Oncology, 2017, 12, 277-288.	1.7	39
49	Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. Critical Reviews in Oncology/Hematology, 2017, 113, 171-190.	2.0	22
50	A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010) Journal of Clinical Oncology, 2017, 35, TPS4598-TPS4598.	0.8	23
51	A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts) Journal of Clinical Oncology, 2017, 35, 431-431.	0.8	59
52	Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. Oncotarget, 2017, 8, 30410-30421.	0.8	19
53	Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. Oncologist, 2016, 21, 535-536i.	1.9	54
54	Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. Cell Reports, 2016, 15, 1134-1143.	2.9	96

CRISTINA SUÃIREZ

#	Article	IF	CITATIONS
55	Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. Cancer Treatment Reviews, 2016, 50, 208-216.	3.4	19
56	Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations. Targeted Oncology, 2016, 11, 129-141.	1.7	3
57	Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC) Journal of Clinical Oncology, 2016, 34, 4557-4557.	0.8	4
58	Patient-derived AVATAR mouse models to predict prognosis in advanced renal cell carcinoma Journal of Clinical Oncology, 2016, 34, 551-551.	0.8	2
59	Integrated analysis of mRNA and miRNA to unravel novel mechanisms of sunitinib long term response in mRCC Journal of Clinical Oncology, 2016, 34, e16080-e16080.	0.8	0
60	New advances in genitourinary cancer: evidence gathered in 2014. Cancer and Metastasis Reviews, 2015, 34, 443-464.	2.7	4
61	Renal cell carcinoma avatar mouse models for the personalized cancer therapy era Journal of Clinical Oncology, 2015, 33, e15627-e15627.	0.8	0
62	Phase I Study of Sunitinib in Combination With Gemcitabine and Capecitabine for First-Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma. Oncologist, 2014, 19, 917-918.	1.9	4
63	Efficacy and Safety of Fosfomycin Plus Imipenem as Rescue Therapy for Complicated Bacteremia and Endocarditis Due to Methicillin-Resistant Staphylococcus aureus: A Multicenter Clinical Trial. Clinical Infectious Diseases, 2014, 59, 1105-1112.	2.9	67
64	A prospective observational study of metastatic renal cell carcinoma (mRCC) prior to initiation of systemic therapy Journal of Clinical Oncology, 2014, 32, 4520-4520.	0.8	7
65	Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with chemoradiotherapy in newly diagnosed malignant gliomas Journal of Clinical Oncology, 2013, 31, 2039-2039.	0.8	2
66	C-MYC, HER2, and HER3 expression in localized prostate cancer (PC) treated with radical radiotherapy: Modulation by statins use and correlation with time to progression Journal of Clinical Oncology, 2013, 31, e16045-e16045.	0.8	0
67	Phase II clinical and pharmacokinetic (PK) trial of zalypsis (Z) in patients with urothelial carcinoma (UC) progressing after a first-line platinum-based regimen Journal of Clinical Oncology, 2012, 30, e15001-e15001.	0.8	0
68	An observational study of metastatic renal cell carcinoma patients prior to initiation of initial systemic therapy Journal of Clinical Oncology, 2012, 30, TPS4679-TPS4679.	0.8	0
69	Senescence, a new concept in pathologic response evaluation of rectal carcinomas (RC) after neoadjuvant treatment Journal of Clinical Oncology, 2012, 30, e21021-e21021.	0.8	0
70	Molecular basis for the treatment of renal cell carcinoma. Clinical and Translational Oncology, 2010, 12, 15-21.	1.2	17
71	Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. International Journal of Infectious Diseases, 2010, 14, e73-e78.	1.5	48
72	Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections. Journal of Infection, 2009, 58, 285-290.	1.7	29

#	ARTICLE	IF	CITATIONS
73	Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. Clinical Drug Investigation, 0, , .	1.1	ο